Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

172
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
172
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

222
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
222
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

446
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
446
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
145

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Military-civilian partnerships in the South Puget Sound: Relationships for healthcare readiness and emergency preparedness.

American journal of surgery·2026
Same author

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same author

Investigating optimal warming techniques for hypothermia in a swine model of ischemia.

American journal of surgery·2026
Same author

The SAGES MASTERS Program: top 10 papers on intracorporeal anastomosis in right colectomy.

Surgical endoscopy·2025
Same author

A pilot study on the impact of da Vinci 5's force feedback on clinical outcomes: Does it lead to less tissue trauma in colorectal surgery?

American journal of surgery·2025
Same author

Breaking point: Musculoskeletal combat injuries in Iraq, Afghanistan, and Syria-Epidemiology and future directions of care on the battlefield after over two decades of war.

The journal of trauma and acute care surgery·2025
Same journal

Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026
Same journal

Beyond the Scalpel's Reach.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Society.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Hospitals.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions for Providers.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Patients Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K

Clostridioides difficile Colitis.

Luke Pumiglia1, Lexi Wilson2, Laila Rashidi3

  • 1Department of General Surgery, Madigan Army Medical Center, 9040 Jackson Avenue, Joint Base Lewis-McChord, WA 98431, USA.

The Surgical Clinics of North America
|April 27, 2024
PubMed
Summary
This summary is machine-generated.

Clostridioides difficile colitis, often hospital-acquired diarrhea, is treated with fidaxomicin. Recurrent cases and high-risk populations may benefit from fidaxomicin or bezlotoxumab, emphasizing antibiotic stewardship.

Keywords:
Clostridioides difficile colitisFidaxomicinFulminant colitisHospital-acquired diarrheaToxins

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K

Related Experiment Videos

Last Updated: Jun 27, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Microbiology

Background:

  • Clostridioides difficile colitis is a significant cause of hospital-acquired diarrhea.
  • It is frequently associated with prior antibiotic use.
  • Symptoms range from watery diarrhea to severe manifestations like shock or megacolon in fulminant cases.

Purpose of the Study:

  • To outline the treatment strategies for Clostridioides difficile colitis.
  • To highlight the management of both nonfulminant and fulminant disease presentations.
  • To emphasize preventative measures including antibiotic stewardship.

Main Methods:

  • Review of current clinical guidelines and therapeutic options for Clostridioides difficile colitis.
  • Discussion of pharmacological treatments including fidaxomicin and bezlotoxumab.
  • Emphasis on the role of antibiotic stewardship in prevention.

Main Results:

  • Nonfulminant Clostridioides difficile colitis is primarily treated with oral fidaxomicin.
  • Recurrent episodes of C. difficile colitis also warrant fidaxomicin treatment.
  • Bezlotoxumab is an option for high-risk populations prone to recurrence.
  • Fulminant disease requires aggressive medical management and surgical consultation.

Conclusions:

  • Fidaxomicin is a key treatment for both initial and recurrent Clostridioides difficile colitis.
  • Bezlotoxumab offers an additional therapeutic option for specific patient groups.
  • Preventing C. difficile colitis hinges on effective antibiotic stewardship programs.